There is increasing demand for the inclusion of gut microbiome assessments in clinical trials and clinical trial research. Eurofins ADME BIOANALYSES’ launch of GA-map® Dysbiosis Test, a CE marked standardised gut microbiome test by Eurofins ADME BIOANALYSES will enhance its comprehensive microbiome service offering for its clinical research customers.

Gut microbiome profiling is increasingly required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due both to the impact new pharmaceuticals can have on the microbiome and the fact that the microbiota composition itself may greatly affect the response to treatment. GA provides the first CE-marked and standardised microbiome test to profile and compare an imbalanced microbiota to healthy references. The standardised GA-map Test is based on a pre-determined targets approach (PDT) and is establishing itself as a valuable tool in drug development, clinical research and routine diagnostics.

Ronny Hermansen, CEO, Genetic Analysis comments: “GA is proud to have Eurofins ADME BIOANALYSES as a partner in the clinical research field. To map and unlock the bacteria present in the gut is instrumental for developing better treatment regimes. The GA-map platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation”.

This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the below contact person, for publication on 19 October 2021.

For further information, please contact:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development.  The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com

About Eurofins ADME BIOANALYSES:

Eurofins ADME BIOANALYSES is a Contract Research Organisation providing diverse services to the pharmaceutical industry in the fields of pharmacokinetics, pharmacodynamics and drug metabolism. Based at a site in the heart of Southern France we have over 2000m2 of laboratory and office space. Eurofins ADME BIOANALYSES have five business units which, working cooperatively between each other and in partnership with other Eurofins entities, can offer the full range of pre-clinical and clinical DMPK services; small molecule bioanalysis, large molecule bioanalysis, biomarkers, dermal absorption, and in vivo studies. Through regular investments in equipment and ongoing staff training, Eurofins ADME BIOANALYSES ensures optimisation of registration timelines for our clients in the pharmaceutical, cosmetic and nutrition industries. Eurofins ADME BIOANALYSES’ primary objective is to keep increasing its capacities and range of service offerings whilst remaining a gold standard partner for its clients. www.eurofins.com/biopharma-services/adme/

About Eurofins – the global leader in bio-analysis:

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing.

With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins shares are listed on Euronext Paris Stock Exchange.